Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact its products' regulatory and commercial prospects [5] - Specific claims include the lack of necessary controls for third-party manufacturers, increased risk of confounded study results, and overstated business and financial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5]

Core Insights - CARsgen Therapeutics has presented promising results from a Phase Ib clinical trial of satricabtagene autoleucel ("satri-cel") for pancreatic cancer at the ESMO Congress 2025, marking a significant advancement in CAR T-cell therapy for solid tumors [1][4][6] Clinical Trial Details - The trial involved patients with Claudin18.2 positive pancreatic ductal adenocarcinoma (PDAC) who had undergone curative-intent resection and showed elevated CA19-9 levels post-chemotherapy [2][3] - Six patients were infused with satri-cel, with a median follow-up of 6.05 months, where only one patient experienced disease recurrence, indicating a promising disease-free survival rate [4][5] Efficacy and Safety - The 9-month disease-free survival (DFS) rate was reported at 83.3%, with significant declines in CA19-9 levels observed in 83.3% of patients, ranging from 51.3% to 96.1% [4][6] - Adverse effects included Grade 1 or 2 cytokine release syndrome (CRS) in all patients, with one case of Grade 3 CRS, which was manageable [5] Future Directions - The company is advancing clinical trials for satri-cel in gastric cancer adjuvant therapy and aims to provide better treatment options for a broader patient population [6][8] - Satri-cel has received various designations from regulatory bodies, including Breakthrough Therapy Designation and Priority Review from the CDE in China, indicating its potential as a first-in-class therapy [7]

Group 1 - The "Sterling 20" group has been formed by some of the UK's largest pension providers and insurers to increase investments in infrastructure and fast-growing sectors like artificial intelligence and fintech [1][2] - The group will collaborate with the UK's Office for Investment to identify regional investment opportunities, coinciding with a regional investment summit hosted by the government [2] - Legal & General Group Plc and the government-backed pension fund Nest have committed billions to enhance affordable housing and improve broadband in rural areas [3] Group 2 - The UK Chancellor has urged pension funds to enhance their support for the domestic economy, especially after observing years of outflows from domestic assets [4] - Although UK pension funds have doubled their investment in unlisted equities over the past year, they still fall short of the levels required to fulfill their commitment to support private businesses [4] - The government has indicated it may exercise "reserve power" to compel pension funds to invest in the domestic economy, a move opposed by investment managers who argue that investment decisions should be left to clients [5]

Core Insights - Ascletis Pharma Inc. has completed enrollment in a U.S. Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation of the small molecule GLP-1 receptor agonist ASC30, targeting obesity treatment [3][4] - The Phase IIa study is a 12-week, randomized, double-blind, placebo-controlled trial involving 65 participants with obesity or overweight, all having at least one weight-related comorbidity [4][3] - Topline data from the study is expected in the first quarter of 2026, marking a significant milestone in the development of ASC30 [2][7] Study Details - The Phase IIa study evaluates the efficacy, safety, and tolerability of ASC30 in participants with a body mass index (BMI) of 30 kg/m or higher, or 27 kg/m but less than 30 kg/m [4] - The study consists of three cohorts with different doses, totaling 65 participants [4] - The ultra-long-acting SQ depot formulation of ASC30 demonstrated a 46-day observed half-life in a Phase Ib study, supporting its once-monthly administration [2][5] Technology and Development - ASC30 is developed using Ascletis' Ultra-Long-Acting Platform (ULAP), which allows for a longer half-life compared to traditional albumin-dependent technologies [6][7] - The proprietary formulation shows a favorable peak-to-trough ratio of approximately 1.5 to 1, indicating its potential as a once-monthly treatment option for obesity [7][6] - ASC30 is a first and only investigational small molecule GLP-1R biased agonist designed for both oral and subcutaneous administration [9][10] Company Overview - Ascletis Pharma Inc. is a biotechnology company focused on developing therapeutics for metabolic diseases, utilizing advanced technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) [10] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [10]

Core Viewpoint - Oil prices declined in early Asian trading due to expectations of a market surplus [1] Group 1 - The decline in oil prices is attributed to the anticipation of an oversupply in the market [1]

Company: Golden Agri-Resources LimitedBloomberg ticker: GGR SPMarket cap: US$3,254mBackground: Golden Agri-Resources Limited, an Indonesian company, is a leading global producer of palm oil. It operates large-scale plantations and mills across Indonesia. The company’s business encompasses the entire palm oil value chain, from cultivation to processing and distribution of its diverse brands, including Filma and Kuncimas.World Class Benchmarking of Golden Agri-Resources Ltd Profitable Growth rank of 7 was up ...

Core Insights - WePlay collaborates with Care Bears to launch a "Halloween Carnival Party," emphasizing love and joy during the festive season [1][3] - The event features interactive games and activities aimed at overcoming negativity and promoting friendship among players [3][5] Company Overview - WePlay, a flagship product of WeJoy based in Singapore, focuses on blending gaming and social interaction for young users aged 18-25 [4] - The platform offers various interactive games, facilitating social connections while providing entertainment [4] Market Position - WePlay ranks highly on the App Store and Google Play free charts in the Middle East, Southeast Asia, and Taiwan, indicating its popularity among young users [5] - The collaboration with Care Bears is part of WePlay's strategy to expand global IP partnerships, following previous collaborations with other well-known IPs [5] Event Details - The Halloween Carnival Party runs from October 17 to October 31, featuring themed activities and exclusive rewards [3][6] - New Care Bears-themed virtual gifts and limited edition skins are introduced to enhance user engagement during the event [6]

Bausch + Lomb is seen as a potential buyer for the contact-lens unit and the CEO said he would be interested. ...

China Shipping containers are seen at the port of Oakland as trade tensions continue over U.S. tariffs with China, in Oakland, California, on May 12, 2025.BEIJING — China's economy likely slowed in the third quarter, with official data due Monday expected to confirm weaker growth, according to analysts polled by Reuters.The analysts forecast gross domestic product growth rose 4.8% in the July-to-September period from a year ago, easing from 5.2% in the previous quarter.Fixed-asset investment, which includes ...

Core Viewpoint - Warren Buffett's Berkshire Hathaway has significantly increased its investment in Chevron, purchasing nearly 3.5 million shares worth approximately $520 million, marking a notable shift in strategy after being a net seller in recent quarters [4][10]. Company Summary - Chevron has been a favored stock of Buffett since 2020, with Berkshire Hathaway initially acquiring shares at around $80. The position has seen aggressive management, including a 50% reduction in early 2021 and a substantial acquisition of 121 million shares in 2022 [3][4]. - Currently, Chevron trades at a price-to-earnings ratio of 19, which is lower than the S&P 500's 31, making it appear attractive in a market that lacks obvious value [6][9]. - The company maintains a strong free cash flow, supporting a dividend yield of 4.5%, despite stagnant revenue growth [6][9]. Industry Summary - The oil industry faces challenges, including a significant drop in oil prices, which have fallen below $60 per barrel, and rising inventories expected to lead to surpluses by 2026 [7][8]. - Chevron's integrated business model, which includes refining and chemical production, allows it to manage industry cyclicality effectively. The CEO emphasizes cost controls and capital efficiency to stabilize profits amid low oil prices [8]. - Despite current challenges, Chevron remains a compelling investment for those seeking value in a potentially bearish market, with its dividend yield and consistent free cash flow providing a buffer against downturns [9][10].